NAV

Xylazine

Targets (1)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Xylazine
Accession Number
DB11477
Description

Xylazine is a clonidine analog which acts as an agonist at α2 adrenoceptors. Veterinarians also use xylazine as an emetic, especially in cats.

Type
Small Molecule
Groups
Vet approved
Structure
Thumb
3D
Similar Structures
Weight
Average: 220.33
Monoisotopic: 220.103419697
Chemical Formula
C12H16N2S
Synonyms
  • Xilazina
  • Xylazinum
External IDs
  • BAY 1470
  • WH 7286

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AAlpha-2 adrenergic receptors
agonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AcebutololThe therapeutic efficacy of Xylazine can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Xylazine.
AcemetacinThe risk or severity of hypertension can be increased when Xylazine is combined with Acemetacin.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Xylazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Xylazine.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Xylazine.
AclidiniumXylazine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Xylazine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Xylazine.
AlclofenacThe risk or severity of hypertension can be increased when Xylazine is combined with Alclofenac.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Xylazine hydrochlorideNGC3S0882S23076-35-9QYEFBJRXKKSABU-UHFFFAOYSA-N
International/Other Brands
Anased / Chanazine / Rompun / Sedazine

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as m-xylenes. These are aromatic compounds that contain a m-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 3-positions.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Xylenes
Direct Parent
m-Xylenes
Alternative Parents
Aniline and substituted anilines / 1,3-thiazines / Isothioureas / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Hydrocarbon derivative / Isothiourea / M-xylene / Meta-thiazine / Organic 1,3-dipolar compound / Organic nitrogen compound / Organoheterocyclic compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
2KFG9TP5V8
CAS number
7361-61-7
InChI Key
BPICBUSOMSTKRF-UHFFFAOYSA-N
InChI
InChI=1S/C12H16N2S/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12/h3,5-6H,4,7-8H2,1-2H3,(H,13,14)
IUPAC Name
N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine
SMILES
CC1=CC=CC(C)=C1NC1=NCCCS1

References

General References
  1. Knight AP: Xylazine. J Am Vet Med Assoc. 1980 Mar 1;176(5):454-5. [PubMed:7358565]
  2. Beasley M: Xylazine. N Z Vet J. 1995 Jun;43(3):125. [PubMed:16031828]
  3. Fyffe JJ: Xylazine. N Z Vet J. 1995 Oct;43(5):204-5. [PubMed:16031851]
  4. Folkers ER: Xylazine precaution. J Am Vet Med Assoc. 1980 May 15;176(10 Pt 1):956. [PubMed:7189750]
  5. Haskins SC, Patz JD, Farver TB: Xylazine and xylazine-ketamine in dogs. Am J Vet Res. 1986 Mar;47(3):636-41. [PubMed:3963565]
  6. Haigh JC: Misuse of xylazine. Can Vet J. 1988 Oct;29(10):782-4. [PubMed:17423135]
  7. Wollen TS: Xylazine and tranquilizers. Mod Vet Pract. 1978 Feb;59(2):80-1. [PubMed:24166]
  8. Authors unspecified: More comments on xylazine. J Am Vet Med Assoc. 1985 Sep 1;187(5):456-7. [PubMed:4055470]
  9. Mbiuki SM: Xylazine analgesia in cattle. Vet Med Small Anim Clin. 1981 Oct;76(10):1463-4. [PubMed:6916527]
  10. Hsu WH: Xylazine-atropine interaction. Am J Vet Res. 1983 May;44(5):928. [PubMed:6870002]
KEGG Drug
D08683
ChemSpider
5505
BindingDB
50027069
RxNav
1099660
ChEBI
92386
ChEMBL
CHEMBL297362
ZINC
ZINC000000002248
Wikipedia
Xylazine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.261 mg/mLALOGPS
logP3.23ALOGPS
logP3.63ChemAxon
logS-2.9ALOGPS
pKa (Strongest Basic)6.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.82 m3·mol-1ChemAxon
Polarizability24.76 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0229-3920000000-b822873abe0cc77b6500

Targets

Details1. Alpha-2 adrenergic receptors (Protein Group)
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Components:
NameUniProt ID
Alpha-2A adrenergic receptorP08913
Alpha-2B adrenergic receptorP18089
Alpha-2C adrenergic receptorP18825
References
  1. Schwartz DD, Clark TP: Affinity of detomidine, medetomidine and xylazine for alpha-2 adrenergic receptor subtypes. J Vet Pharmacol Ther. 1998 Apr;21(2):107-11. [PubMed:9597647]

Drug created on February 25, 2016 12:05 / Updated on June 12, 2020 10:53